Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akari Therapeutics PLC

0.8191
+0.00670.82%
Post-market: 0.7811-0.0380-4.64%18:37 EDT
Volume:22.86K
Turnover:18.75K
Market Cap:26.71M
PE:-1.51
High:0.8340
Open:0.8201
Low:0.8001
Close:0.8124
52wk High:3.85
52wk Low:0.5714
Shares:32.61M
Float Shares:5.62M
Volume Ratio:0.03
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5428
EPS(LYR):-1.6570
ROE:-112.02%
ROA:-28.56%
PB:1.04
PE(LYR):-0.49

Loading ...

Company Profile

Company Name:
Akari Therapeutics PLC
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
9
Office Location:
22 Boston Wharf Road,Floor 7,Boston,Massachusetts,United States
Zip Code:
02210
Fax:
929 274 7553
Introduction:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.

Directors

Name
Position
Abizer Gaslightwala
Director,President and Chief Executive Officer
Hoyoung Huh
Chairman
James Neal
Director
Robert Bazemore
Director
Samir R. Patel
Director
Sandip I. Patel
Director

Shareholders

Name
Position
Abizer Gaslightwala
Director,President and Chief Executive Officer